Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 4/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7865220 | 0.92 | REN (0.48) | RENGPR119PDE4BPIK3CDUSP30 | |
| SCHEMBL7858461 | 0.86 | REN (0.50) | RENGPR119PDE4BPIK3CD | |
| SCHEMBL7864042 | 0.82 | REN (0.76) | REN | |
| SCHEMBL7864049 | 0.80 | REN (0.51) | RENGPR119PDE4B | |
| SCHEMBL7866725 | 0.79 | REN (0.52) | RENGPR119PDE4B | |
| SCHEMBL7865225 | 0.77 | REN (0.47) | RENGPR119PDE4BPIK3CDUSP30 | |
| SCHEMBL7866462 | 0.76 | REN (0.54) | RENGPR119PDE4B | |
| SCHEMBL7866500 | 0.72 | REN (0.71) | RENGPR119 | |
| SCHEMBL89513 | 0.72 | PDE4B (0.54) | PDE4B | |
| SCHEMBL7866711 | 0.72 | REN (0.50) | RENGPR119PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2527338-B1 | N5-(2-ETHOXYETHYL)-N3-(2-PYRIDINYL) -3,5-PIPERIDINEDICARBOXAMIDE DERIVATIVES FOR USE AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| EP-2181105-B1 | N5-(2-ETHOXYETHYL)-N3-(2-PYRIDINYL)-3,5-PIPERIDINEDICARBOXAMIDE DERIVATIVES FOR USE AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2015-04-29 | — | — | EP | disclosed |
| US-8497286-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-8497286-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-8383650-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-8383650-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-20130005770-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2013-01-03 | — | — | US | disclosed |
| US-20130005770-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2013-01-03 | — | — | US | disclosed |
| WO-2009000811-A1 | N5-(2-ETHOXYETHYL)-N3-(2-PYRIDINYL)-3,5-PIPERIDINEDICARBOXAMIDE DERIVATIVES FOR USE AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2008-12-31 | — | — | WO | disclosed |
| US-20080319018-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20080319018-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319018-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | REN 1/4885GPR119 471/4885PDE4B 2237/4885 |
| US-20130005770-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | REN 1/4885GPR119 471/4885PDE4B 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.